---
date: "2024-01-13 07:08:41" # 2021-07-14
title: "Lantheus (NASDAQ: LNTH) Receives Buy Rating Upgrade from StockNews.com"
# image: "images/plots/{{titleSlag}}.png"
author: "justin-guese"
draft: false
---
tickers: <a href='https://finance.yahoo.com/quote/LNTH' target='_blank'>LNTH</a>, <a href='https://finance.yahoo.com/quote/BK' target='_blank'>BK</a> 

source: <a href='https://www.defenseworld.net/2024/01/13/lantheus-nasdaqlnth-lifted-to-buy-at-stocknews-com.html' target='_blank'>Stocknews.com</a>

#### tickers affected by this

| ticker | polarity | why? |
|------------|------------|------------|
| LNTH | positively | The upgrade from a "hold" to a "buy" rating by StockNews.com suggests that there is increased confidence in the future performance of LNTH, potentially leading to higher demand and a positive impact on the stock price. |
| BK | positively | Based on the information provided in the article, it is not evident that the ticker BK would be directly affected positively. |



#### our strategies and bots using these tickers

None so far...

## summary

# Lantheus (NASDAQ:LNTH) Lifted to Buy at StockNews.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been upgraded from a "hold" rating to a "buy" rating by stock analysts at StockNews.com. The upgrade comes as a result of a research report issued to clients and investors on Saturday. Other analysts have also issued research reports about the stock.

Mizuho, for instance, restated a "buy" rating and issued a $125.00 target price on shares of Lantheus in a research report on October 4th. JMP Securities also dropped their price target on shares of Lantheus from $130.00 to $100.00 and set a "market outperform" rating for the company on November 3rd. Truist Financial reissued a "buy" rating and set a $110.00 target price on shares of Lantheus on October 4th.

However, not all analysts are as positive about the stock. William Blair downgraded shares of Lantheus from an "outperform" rating to a "market perform" rating in a research note on December 18th. Despite this, the overall consensus rating for the stock, according to data from MarketBeat, is "Moderate Buy" with an average price target of $108.14.

Lantheus opened at $56.24 on Friday, with a 52 week low of $50.87 and a 52 week high of $100.85. The company has a market cap of $3.85 billion, a P/E ratio of 39.33, and a beta of 0.54. Its 50-day simple moving average is $66.25, and its 200-day simple moving average is $70.20. Lantheus last announced its quarterly earnings results on November 2nd, reporting earnings per share of $1.29 for the quarter, beating analysts' consensus estimates of $1.19 by $0.10. The company had revenue of $319.95 million for the quarter, compared to analyst estimates of $315.01 million. Lantheus had a net margin of 8.63% and a return on equity of 70.13%. Analysts are currently forecasting that Lantheus will post earnings per share of $5.37 for the current year.

In terms of insider activity, President Paul Blanchfield sold 1,500 shares of the business's stock in a transaction that occurred on November 16th. The shares were sold at an average price of $67.96, resulting in a total value of $101,940. Following the sale, Blanchfield now owns 88,651 shares of the company's stock, valued at $6,024,721.96. CEO Mary Anne Heino also sold 11,780 shares of the company's stock on November 13th, at an average price of $63.72, totaling $750,621.60. Heino now owns 317,687 shares in the company, valued at approximately $20,243,015.64. Overall, insiders have sold a total of 13,621 shares of company stock, valued at $874,239, over the last quarter. Insiders currently own 1.50% of the company's stock.

A number of hedge funds and institutional investors have recently bought and sold shares of Lantheus stock. Fairfield Bush & CO. purchased a new stake in shares of Lantheus in the 1st quarter valued at $177,000. Raymond James & Associates purchased a new stake in Lantheus during the 1st quarter valued at $856,000. Bank of New York Mellon Corp boosted its position in Lantheus by 2.7% during the 1st quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider's stock valued at $34,791,000 after buying an additional 16,422 shares during the period. American Century Companies Inc. also boosted its position in Lantheus by 14.4% during the 1st quarter. They now own 19,235 shares of the medical equipment provider's stock valued at $1,064,000. Finally, HighTower Advisors LLC bought a new position in Lantheus in the 1st quarter worth $354,000. Hedge funds and institutional investors currently own 99.06% of the company's stock.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products used in the diagnosis and treatment of various diseases worldwide. Its product offerings include DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify areas of reduced blood flow in the brain due to stroke; and Cardiolite, an injectable imaging agent. 

In conclusion, Lantheus Holdings, Inc. has recently been upgraded from a "hold" rating to a "buy" rating by StockNews.com. The company has received positive ratings from several analysts, with a consensus rating of "Moderate Buy" and an average price target of $108.14. With its recent earnings beat and positive insider activity, Lantheus shows promise for the future.